Acute Otitis Media
Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order
to see the Introduction page.
Acute otitis media (AOM), characterized by the rapid onset of symptoms like ear pain and fever, is one of the most frequent childhood illnesses. It is the most common diagnosis leading to an antibiotic prescription in the U.S., in fact, AOM accounts for one-half of all antibiotic use in children.
The controversy over the use of antibiotics for AOM has been ongoing for many years. Most children will recover without antibiotics, and national experts recommend "watchful waiting" as the first step in management for many children. Despite this endorsement, watchful waiting is used in only 15% of AOM cases, with physicians citing parental reluctance as the number one barrier to use.
This issue outlines the current management recommendations for AOM, including watchful waiting, antibiotic therapy, and symptomatic treatment. Antibiotic options for penicillin-allergic children and those who fail first-line therapy are included. Preventive measures you can recommend to parents, including risk factors worth avoiding and immunizations that reduce risk, are detailed in the Rx Patient Connection insert.
Publication Date: 02/01/2008
Expiration Date: 03/01/2011
CE Credit: 1.5 (0.15 CEU)
Type of Activity: Knowledge-based
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc.
The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and
is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased,
balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic
area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure
that every program presents information that is current, accurate, relevant to "real world" health care
providers, and written in an easy reading, "plain English" style.
Jennifer Le, Pharm.D., BCPS, Infectious Diseases (including Pediatric and Adult) Pharmacist; Assistant Professor of Pharmacy Practice and Administration, Western University of Health Sciences, College of Pharmacy, Pomona, CA; in affiliation with Miller Children's Hospital and Long Beach Memorial Medical Center, Long Beach, CA.
Dr. Le has served as a consultant and speaker for and has received research funding from Pfizer, Inc. Vantin® (cefpodoxime) is distributed by the Pharmacia & Upjohn Co. division of Pfizer, Inc. Zithromax® (azithromycin) is distributed by the Pfizer Labs division of Pfizer, Inc.
Guest Editorial Advisor
Cynthia Chan Huang, Pharm.D.
This accredited program is targeted to pharmacists and nurses.
Goals & Objectives
At the conclusion of this program, participants will be able to:
- Describe the risk factors for acute otitis media (AOM) and the
parameters used for diagnosis.
- Summarize the current management recommendations for AOM.
Include the role of immunizations and the option of initial
observation versus initial treatment with antibiotics.
- Individualize antibiotic treatment options for AOM based on
bacterial resistance, severity of illness and penicillin allergy.
- Discuss usual doses, common side effects and appropriate administration
of the antibiotics commonly used for treatment of AOM.
The Rx Consultant is a publication of Continuing Education Network, Inc.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education as a
provider of continuing pharmacy education.
Continuing Education Network is approved by the California Board of Registered Nursing, Provider Number CEP 13118. Programs approved by CA BRN are accepted by most State Boards of Nursing.
ACPE Universal Activity Number: 428-0000-08-002-H01-P
Exam & Credit Statement Procedures
Upon successful completion of this program and the post test (70%), 1.5 hours of continuing education credit will be awarded. To receive credit and your exam score, please complete the exam questions and
Editorial and Review Board
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
School of Pharmacy
University of California San Francisco
San Francisco, CA
Richard Ron Finley, B.S. Pharm.,R.Ph.
Clinical Pharmacist (volunteer faculty)
University of California, San Francisco (UCSF) Memory and Aging Center
Lecturer (Emeritus) UCSF, Department of Clinical Pharmacy
Health Sciences Clinical Professor, UCSF School of Pharmacy
San Francisco, CA
Ray Dolby Brain Health Center, Sutter Health/CPMC
San Francisco, CA
Consult Pharmacist Aging and Adult Health Services
San Francisco Health Department
San Francisco, CA
Julio R. Lopez, PharmD, FCSHP
Chief of Pharmacy Service
VA Northern California Health Care System
Adjunct Clinical Professor
College of Pharmacy
Assistant Clinical Professor
School of Pharmacy
University of California, San Francisco
San Francisco, CA Adjunct Professor
Thomas J. Long School of Pharmacy
University of the Pacific
Visiting Associate Professor and Lecturer
Samuel Merritt University
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Clinical Assistant Professor, Pharmacy Practice
Wayne State University
Ambulatory Care Specialist - Diabetes
Health Centers Detroit Medical Group
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
About the Rx Consultant
The Rx Consultant is a monthly publication dedicated to providing health care professionals with the information they need to
educate patients about drugs and manage drug therapy. The reader is responsible for confirming
the information presented here and interpreting it in relation to each patient's specific situation before utilizing the information.
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)